• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Medical Officer Pakola Steve covered exercise/tax liability with 5,263 shares, decreasing direct ownership by 2% to 210,717 units (SEC Form 4)

    4/4/25 5:17:02 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGNX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    PAKOLA STEVE

    (Last) (First) (Middle)
    C/O REGENXBIO INC.
    9804 MEDICAL CENTER DRIVE

    (Street)
    ROCKVILLE MD 20850

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    REGENXBIO Inc. [ RGNX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/01/2025 F 5,263(1) D $8.07 210,717 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2025
    Remarks:
    /s/ Patrick J. Christmas as attorney-in-fact 04/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RGNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGNX

    DatePrice TargetRatingAnalyst
    2/11/2025$38.00 → $14.00Buy → Neutral
    Goldman
    2/7/2025$27.00Outperform
    Raymond James
    11/15/2024$22.00Overweight
    Morgan Stanley
    10/10/2024$18.00Outperform
    Raymond James
    6/7/2024$38.00Buy
    Goldman
    3/11/2024$36.00Buy
    H.C. Wainwright
    3/8/2024$20.00 → $35.00Sector Perform → Outperform
    RBC Capital Mkts
    3/6/2024$37.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $RGNX
    SEC Filings

    See more
    • SEC Form EFFECT filed by REGENXBIO Inc.

      EFFECT - REGENXBIO Inc. (0001590877) (Filer)

      4/15/25 12:15:16 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by REGENXBIO Inc.

      DEFA14A - REGENXBIO Inc. (0001590877) (Filer)

      4/8/25 4:20:03 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by REGENXBIO Inc.

      DEF 14A - REGENXBIO Inc. (0001590877) (Filer)

      4/8/25 4:15:18 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Financials

    Live finance-specific insights

    See more
    • REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mi

      4/30/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a leading

      2/26/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-s

      10/30/24 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Christmas Patrick J. covered exercise/tax liability with 4,700 shares, decreasing direct ownership by 3% to 156,110 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      4/4/25 5:17:19 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Pakola Steve covered exercise/tax liability with 5,263 shares, decreasing direct ownership by 2% to 210,717 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      4/4/25 5:17:02 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Danos Olivier covered exercise/tax liability with 5,452 shares, decreasing direct ownership by 2% to 226,348 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      4/4/25 5:16:46 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • REGENXBIO downgraded by Goldman with a new price target

      Goldman downgraded REGENXBIO from Buy to Neutral and set a new price target of $14.00 from $38.00 previously

      2/11/25 7:12:20 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on REGENXBIO with a new price target

      Raymond James resumed coverage of REGENXBIO with a rating of Outperform and set a new price target of $27.00

      2/7/25 8:29:59 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on REGENXBIO with a new price target

      Morgan Stanley resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $22.00

      11/15/24 8:17:57 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

      ROCKVILLE, Md., May 8, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, May 13 through 17, 2025. The presentations highlight REGENXBIO's leading end-to-end capabilities across research and early development, late-stage clinical development, and gene therapy manufacturing. Presentations include encore data from late-stage clinical trials of RGX-121 (clemidsogene lanparvovec) for the treatment of MPS II and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as preclinical research supporting the novel construct of RGX-202 with the C-Terminal dom

      5/8/25 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Participate in Upcoming Investor Conferences

      ROCKVILLE, Md., May 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced it will participate in the following investor conferences: BofA Securities Health Care Conference 2025Presentation: Tuesday, May 13, 2025 at 5:00 p.m. PTLocation: Las Vegas, NV RBC Global Healthcare ConferenceFireside Chat: Tuesday, May 20, 2025 at 11:30 a.m. ETLocation: New York, NY H.C. Wainwright BioConnectFireside Chat: Tuesday, May 20, 2025 at 4:00 p.m. ETLocation: New York, NY Stifel Virtual Ophthalmology Forum Fireside Chat: Tuesday, May 27, 2025 at 9:30 a.m. ETLocation: Virtual UBS Spring Biotech Conference1x1 Investor Meetings: Tuesday, June 24, 2025Location: New York, NY Live webcasts of select

      5/6/25 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mi

      4/30/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/14/24 9:00:57 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/12/24 4:47:45 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/4/24 1:49:56 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/6/24 6:29:00 PM ET
      $AMTM
      $APO
      $CMA
      $CRI
      Investment Managers
      Finance
      Major Banks
      Apparel
    • REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

      Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years.  "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and

      9/17/24 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO Announces Leadership Transition

      Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE

      6/12/24 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care